×

RNS Number : 8844V

Chamberlin PLC

06 December 2019

 

AIM: CMH

6 December 2019

 

 

CHAMBERLIN PLC

("Chamberlin" or the "Company")

 

 

Contract award for Walsall foundry

 

Chamberlin, the specialist casting and engineering group, is pleased to announce the successful award of new business to supply iron castings, out of the Walsall based foundry to Roadcraft Safety Products ("Roadcraft") based in Somerset.  Roadcraft is a key supplier of "cats eyes" to the UK and a number of overseas highways agencies.

 

Production has now commenced and is expected to reach approximately £0.4 million per annum. Chamberlin's Walsall foundry continues as one of the UK's principal high volume suppliers of bearing housings to the European automotive sector.  The ongoing contract with Roadcraft represents an opportunity to diversify the customer base of the Walsall foundry beyond the automotive sector.

 

Kevin Nolan, Chief Executive of Chamberlin commented:

 

"It is particularly pleasing to be awarded this new business with a new customer outside of the automotive sector in order to reduce our reliance on the production of bearing housings to the automotive sector, upon which our reputation has been built".

 

 

 

Enquiries

 

Chamberlin plc Kevin Nolan, Chief Executive Neil Davies, Finance Director		T: 01922 707100
Cenkos Securities plc (Nominated Adviser and Broker) Russell Cook Katy Birkin		T: 020 7397 8900
KTZ Communications (Financial PR) Katie Tzouliadis Dan Mahoney		T: 020 3178 6378

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTTABFTMBMMBLL

Close

×

RNS Number : 8839V

Chamberlin PLC

06 December 2019

 

AIM: CMH

6 December 2019

 

 

CHAMBERLIN PLC

("Chamberlin" or the "Company")

 

 

Contract award for Scunthorpe foundry

 

Chamberlin, the specialist castings and engineering group, is pleased to announce the award of a significant new order for Russell Ductile Castings Limited, Chamberlin's iron and steel casting foundry based in Scunthorpe.  The new order is for the supply of flap valves for the construction of the Thames Tideway Tunnel.

 

The initial order is for £0.9 million and represents approximately 50% of the total value of the contract which is worth up to £1.8 million.  Production of the valves will commence in the current financial year, although the full benefit of the order will be seen through 2020 and beyond.

 

 

Kevin Nolan, Chief Executive of Chamberlin commented:

 

"In securing this very material order it is pleasing to note that Russell Ductile Castings is one of only a few foundries based in the UK capable of producing the cross section of complex castings required for this project. This order will go a long way towards securing production at the Scunthorpe facility for the foreseeable future".

 

 

 

Enquiries

 

Chamberlin plc Kevin Nolan, Chief Executive Neil Davies, Finance Director		T: 01922 707100
Cenkos Securities plc (Nominated Adviser and Broker) Russell Cook Katy Birkin		T: 020 7397 8900
KTZ Communications (Financial PR) Katie Tzouliadis Dan Mahoney		T: 020 3178 6378

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFSWFMIFUSESE

Close

×

Neville Registrars is delighted to welcome OneView Group Limited as the newest addition to its list of client companies.

 

Close

×

RNS Number : 5212U

Modern Water PLC

25 November 2019

 

 

 

 

 

Modern Water plc

 

("Modern Water", "the Company" or "the Group")

 

 

Modern Water sells its largest-ever AMBC for Korea Salt Production Facility

 

For immediate release	25 November 2019

 

Modern Water plc (AIM: MWG) is pleased to announce that it secured the sale of its largest by volume All-Membrane Brine Concentrator technology ("AMBC"), to be used in South Korea's first deep seawater salt production project. The plant will have capacity for treating approximately 13m3/h, concentrating sea water sourced from a depth of up to 600m. Salt production from seawater offers environmental benefits compared to land-based salt mining, which can result in environmental problems due to the waste it generates and the health hazards posed to salt miners.

 

The AMBC project will be executed by Modern Water, owner of leading technologies for water and wastewater treatment, in conjunction with its partner in China, Hangzhou Shangtuo Environmental Science and Technology Co., Ltd ("Sunup").   

 

Simon Humphrey, CEO of Modern Water commented: "Our partnership with Sunup is capable of delivering our innovative technology directly to customers across China – and now also in Asian markets beyond China, such as South Korea.  This is Modern Water's largest single AMBC plant yet and follows on from various successful plants we have designed with our partners in India and China."  

 

Noah Tan, CEO of Sunup, added: "As the key process in this salt production project we will be using Modern Water's AMBC, the high saline modular concentration technology. AMBC allows our customers to achieve higher concentration levels than traditional membrane techniques and reduces the need for chemicals in salt production.  AMBC is a step-change in efficiency, significantly reducing operating costs for our customers. It is also versatile and can be used across many different industries."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

–Ends–

 

 

For further information:

 

Modern Water plc	+44-(0)20-38273439
Simon Humphrey, Chief Executive
Cairn Financial Advisers LLP (Nominated Adviser)	+44 (0) 207 213 0880
Sandy Jamieson / Tony Rawlinson Ludovico Lazzaretti
Turner Pope Investments (Broker) Andy Thacker / Zoe Alexander	+44 (0) 20 3657 0050

 

Notes to editors:

 

Modern Water is a pioneering and innovative technology company, specialising in membrane water treatment solutions and advanced monitoring products. The Company works for customers in a range of industries across the globe and owns proprietary technologies for use in a diverse range of applications. Modern Water's Monitoring Division has a portfolio of world-leading toxicity and trace metal monitoring products, some of which constitute the regulatory standard. The headline technology of the Company's Membrane Division, called "AMBC", can be used to tackle complex wastewater treatment problems at a reduced cost compared to standard processes, while being simple to operate.

www.modernwater.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

DISLIFEALTLEFIA

Close

×

RNS Number : 9540T

Integumen PLC

20 November 2019

 

AIM share code: SKIN

 

20 November 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen announces successful results of AI water research project

 

Rinocloud AI remotely detects contaminated water with 99.3% accuracy in 3.37 seconds

 

 

Integumen today announces the successful results of a three-year development Remote Automated Water Test research project (RAWTest), using Artificial Intelligence (AI) in a consortium partly funded by the Irish Environmental Protection Agency (EPA).  

 

The Project

The consortium comprised of the Irish Environmental Protection Agency (EPA), Cork Institute of Technology's (CIT) Centre for Advanced Photonics & Process Analysis (Cappa Group), the CIT Nimbus embedded systems research institute and the AI team from Integumen's Rinocloud subsidiary. 

 

Rinocloud's AI platform was used to test water samples from a fully autonomous data buoy deployed on the Inniscarra Water Reservoir in Cork, Ireland, for E.coli, a bacterium that can cause illness in humans, including diarrhoea, abdominal pain, fever and sometimes vomiting.

 

Results: The positive detection of E.coli bacteria in the water was detected with 99.3% accuracy in 3.37 seconds.  This compares to current standard test detection time of between 5-7 days.

 

Gerard Brandon, CEO of Integumen plc, comments:

"Integumen continues to lead the way with practical demonstrations of solutions for real-world problems.  Remote detection of water contamination across the globe is a first and third world problem with future climate change threatening to increase flooding and contribute to water shortages.  This means increased reliance on recycling and recovery of water supplies, which in turn requires wireless monitoring of all water supplies before consumer consumption.  RAWTest, we believe, can contribute to keeping our water, and healthcare, safe."

 

Wireless RAWTest

·      Rinocloud's AI engine analysed wireless transmission of water data for 13 key AI features, which work as indicators, from 1000+ data elements identified by Raman Spectroscopy.

·      Results showed a 99.3% accuracy in identifying E.coli in water

·      A system of exception alarms was set up by email to escalate a positive sample to the appropriate control group

·      All data was immediately available on the secure Rinocloud portal for access by approved parties for immediate action

·      Potential for other microscopic parasite detection, e.g. Cryptosporidium and Giardia, following data samples input.

 

Water Scarcity:

Water scarcity is the lack of freshwater resources to meet water demand.  It affects every continent and was listed in 2019 by the World Economic Forum as one of the largest global risks in terms of potential impact over the next decade[i].

 

The deployment of wireless RAWTest Buoys in water treatment plants would be a world first and have a positive impact on water consumer service metrics, reducing the average length of time water would be shut off in the event of contamination, reduced "boil-water" notices and faster time to restore supply, as well as biological quality.
 

RAWTest Opportunities:

·      With 20 species of Listeria bacterium, every public building including hospitals, hotels, conference halls and senior citizen nursing homes are at risk of contamination

·      Remote detection and analysis of malaria in blood in third world-countries and for military use

·      In-line milking machines could detect mastitis in a single cow, enabling instant action to eliminate contamination with a dairy herd milk collection

·      Early warning system in fermentation processes for ethanol, alcohol and wine producers at risk of bacterial hazard to improve consumer safety, shelf-life stability and longevity

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units: 

 

·      Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services.  Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·      Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·      Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·      Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

---

[i] https://www.weforum.org/reports/the-global-risks-report-2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAEASFNFDPNFFF

Close

×

RNS Number : 1821T

Integumen PLC

13 November 2019

 

AIM share code: SKIN

 

13 November 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen shares revenue to deliver AI data solutions across Parity plc UK NHS clients

 

Trading update provides 2020 guidance of £4m prior to Parity Agreement

 

 

Integumen announces that it has signed Heads of Terms with Parity plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18 December 2019 for the supply of Artificial Intelligent ("AI") software across Parity's National Health Service ("NHS"), Central Government and Private Institutional clients.

 

This Agreement creates an opportunity to cross-sell intelligent data management, extracting value using analytics, with a focus on proving return on investment, to Parity's 150+ institutional clients.  The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.

 

Combined benefits:

·      Recurring shared revenue streams for both Parity and Integumen in 2020

·      Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts

·      Immediate access to 150 public and private institutional clients

·      Trusted approved vendor for Government and private sectors for over 45 years

·      1,000+ data experts and 100+ enterprise sales and office professionals

·      Existing cross-over access to educational institutional research facilities

·      Access to multiple industry, public and private sector distribution routes to market

·      Well defined roadmap to next level business growth for both Parity and Integumen

 

Six-month trading update:

In May 2019, Integumen acquired Rinocloud Limited for £3m to enable LabskinAI to uses the Rinodrive AI platform to provide cloud-based data services to Integumen's Top 20 global skincare clients.  By the end of June 2019, Rinocloud reached monthly profitability, and over the last six months (May to October) exceeds revenue from Labskin this financial year.

 

Outlook:

Since 2018, the Company has seen average sales grow from £5k for consumable, one-off sales to 2019 average sales of £50k as a service contract.  Heading into 2020, Integumen is engaging with multiple top 20 global skin and personal care companies and believes average sales are likely to range between £100k to £500k for data as a service to skincare R&D framework multi-year agreements, providing good visibility of revenue.  Therefore, excluding developments that may arise from Integumen entering into the agreement with Parity Group plc, the Company is guiding 2020 revenues of £4m.

 

Gerard Brandon, CEO of Integumen plc, comments:

"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold, with an extensive, if not exhaustive, list of public and private institutions. We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."

 

Matthew Bayfield, CEO of Parity Group plc, comments:

"Parity is pleased to be partnering with Integumen and rolling out the Drive4Growth AI platform to our client base.  We have been working with many of the same clients for 45 years, so we understand their needs.  With healthcare sector data growth in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions.  The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units: 

 

·      Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services.  Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·      Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·      Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·      Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

About Parity Group: www.parity.net

Parity helps organisations find the right people, skills and data to support data-led business decisions. Providing advice on data and with access to qualified personnel with skills offered, either as a managed service, through resourcing in the contract or permanent market or as part of a learning and development programme.

Income derives from a mix of long-term contracts with public and private sector organisations as well as expanded projects with existing clients as a result of strong relationships and a track record of high client satisfaction. Key highlights comprising of:

·      Over 45 years of expertise in public and private recruitment and service contract sector

·      More than 100 employees across the UK

·      Client numbers exceed 150 in both UK and Ireland

·      Associate numbers supporting client services exceeds 1,000

 

RinoDrive "Drive4Growth": www.rinodrive.com

A fully integrated set of software tools that can ingest data, in any volume, from any source in any format, interact with it, learn from it and enrich it to unlock insights and discoveries.

This data management solution was developed by scientists and engineers with experience in software, sensors, AI, optofluidic research, fintech, green-tech, travel and healthcare.

It was designed to allow interaction, in a cyber-secure environment, with commercially sensitive data, and to share insights across multi-disciplinary teams, generating different data formats, from multiple sources, located in different countries.

RinoDrive delivers big data, AI functionality and world class infrastructure to large companies with big data problems. These include financial services, education and life science companies. Most recently completing the automation of laboratories and application of AI to unearth more knowledge about the skin microbiome. This led to the acquisition in May 2019 by Integumen PLC, to secure access to, and the exploitation of data from some of the largest cosmetic, pharmaceutical and medical companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCFFIFWEFUSELF

Close

×

RNS Number : 4744S

EVR Holdings PLC

06 November 2019

 

                                                                                                              Wednesday, 6th November 2019

 

 

MELODYVR EXTENDS PARTNERSHIP WITH GOOD MORNING AMERICA

 

EVR Holdings plc (AIM:EVRH), the leading creator of virtual reality entertainment content and operator of the MelodyVR platform, is pleased to announce that next Wednesday November 13th the Company will extend its partnership with Good Morning America ("GMA") and ABC to broadcast a landmark event live from the heart of Nashville.

 

A global audience will be able to experience America's most-watched morning show in full immersive 360-degree virtual reality on their smartphones via the MelodyVR app, downloadable from the iOS, Google Play and Oculus app stores (or via this link on.melodyvr.com/App).

 

Transmitted from Music City's iconic Wildhorse Saloon, MelodyVR users will get a unique look at Country Music Association Award nominees Luke Combs and Maddie and Tae, as well as country music legends Trisha Yearwood and Trace Adkins during their appearance on Good Morning America.

 

Thanks to MelodyVR's groundbreaking live-stream VR technology, an unlimited global audience will be able to experience the program up close in full immersive virtual reality.

 

By selecting different Jump Spots — a function that is unique to the MelodyVR platform — viewers can choose their location within the saloon, getting them incredibly close to their music heroes. MelodyVR will also give users a rare glimpse of their favourite country stars behind the scenes.

 

MelodyVR has already proven itself to be a firm favourite of country music fans over the last year, with exclusive virtual reality performances from the likes of CMA nominees Blake Shelton, Thomas Rhett, and Midland, as well as Kelly Clarkson and Hunter Hayes available on the platform.

 

"I don't know if you want me in your living room, but if you do, we made that happen," says double Award nominee Luke Combs. "It's so cool that people around the world can get up close to the show in Nashville with MelodyVR and Good Morning America. CMA Awards day will be so exciting for me after one hell of a year and being able to share that moment with my fans in VR is real special."

 

Anthony Matchett, CEO of MelodyVR says: "We are delighted to be working with the ABC and Good Morning America team again, after recently partnering with them to broadcast Marshmello and Kane Brown in virtual reality during the renowned Summer Concert Series to fans across 15 countries. It's great to be right at the heart of the action during the biggest day in the country music calendar, and it's a privilege to allow fans around the world to feel as though they're right here in Nashville, as award excitement builds."

 

For further information please contact:   EVR Holdings plc Anthony Matchett, Executive Chairman & CEO                                                                            [email protected]

Arden Partners plc: Nominated Advisor and Sole Broker                                                        Tel: +44 (0) 20 7614 5900 Corporate Finance: Ciaran Walsh / Ruari McGirr / Ben Cryer Corporate Broking: Simon Johnson

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAFSUFSMFUSEFF

Close

×

RNS Number : 0577S

ZAIM Credit Systems PLC

04 November 2019

 

Not for release or distribution, directly or indirectly, within, into or in the United States or to or for the account or benefit of persons in the United States, Australia, Canada, Japan or any other jurisdiction where such offer or sale would violate the relevant securities laws of such jurisdiction

 

For Immediate Release

4 November 2019

Zaim Credit Systems Plc

("Zaim Credit" or "the Company")

Admission to Trading

The Directors of Zaim Credit, a regulated microfinance business operating in the Russian Federation, are pleased to announce that following the publication of its prospectus on 30 October 2019 (the "Prospectus") and completion of the placing and subscription of 104,000,000 new ordinary shares of £0.01 each in the Company ("Ordinary Shares") at 2.5p per share ("Placing Price") raising gross proceeds of £2.6 million, the Company's Enlarged Share Capital comprising 436,975,000 Ordinary Shares will be admitted to the Official List (by way of a Standard Listing under Chapter 14 of the Listing Rules) and to trading on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. GMT today under the TIDM "ZAIM" ("Admission"). The Company's ISIN is GB00BK5T9G03 and LEI 213800Z4MI9KSZA2VW72.

Siro Cicconi, Chief Executive Officer commented:

"We are pleased to bring the Company to the London Market. We believe there are excellent prospects to grow our business and look forward reporting further progress in due course."

About the Company

 

Zaim Credit is the holding company of a Russian based financial services company Zaim-Express LLC ("Zaim") which it acquired on 10 September 2019. Zaim is authorised to conduct microfinance activities and included on the State Registry of Microfinance Organisations (the "Registry") maintained initially as a microcredit organisation ("MCO") by the Russian Ministry of Finance and later, by the Central Bank of Russia ("CBR").

 

Zaim's MCC status allows it to engage in microfinance activity in the territory of the Russian Federation and since obtaining its authorised status, Zaim has developed a bespoke IT system, created a distribution network and raised debt capital to fund its loan book.

 

Copies of the Prospectus are available on the Company's website at http://www.zaimcreditsystemsplc.com/en/ and during normal business hours at the registered address of the Company at c/o Hill Dickinson LLP, The Broadgate Tower, 20 Primrose Street, London, EC2A 2EW.

Total Voting Rights

In conformity with Rule 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that as from Admission the total number of voting rights in the Company is 436,975,000. This figure may be used by the Company's shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Director / PDMR Shareholding

As set out more fully in the Prospectus, certain Directors and members of the Company's senior management have been allotted Fee Shares and granted Options on Admission. As the Directors and senior managers are persons discharging managerial responsibilities, copies of the notifications relating to such transactions in the Company's securities are set out in Appendix I at the end of this announcement.

Defined terms in this announcement shall have the same meanings as in the Prospectus.

Enquiries:

Zaim Credit Systems Plc
Simon Retter Siro Cicconi	Tel: +44 (0) 7795 640 616 Tel: +39 33 3886 6733
Beaumont Cornish Limited
Roland Cornish / James Biddle	Tel: +44 (0) 20 7628 3396
Optiva Securities Limited
Jeremy King / Vishal Balasingham	Tel: +44 (0) 20 3137 1902

 

Appendix I

This announcement is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation ("MAR") and the Company confirms that the PDMR's notification obligations under MAR have been satisfied.

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Simon Retter Stonedale Management and Investments Ltd
2	Reason for notification
a)	Position / status	Finance Director
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Ordinary Shares and Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Ordinary Shares and Issue of Options
	Price(s) and volumes(s)	Financial Instrument Price(s) Volumes(s) Ordinary Shares 2.5p 1,600,000 Options* 2.5p 6,450,000 *Options have been issued to Stonedale Management and Investments Ltd of which Simon Retter is the sole director and sole shareholder
d)	Aggregated information	Financial Instrument Price(s) Volumes(s) Total Value Ordinary Shares 2.5p 1,600,000 £40,000 Options* 2.5p 6,450,000 £161,250 *Options have been issued to Stonedale Management and Investments Ltd of which Simon Retter is the sole director and sole shareholder
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Siro Cicconi
2	Reason for notification
a)	Position / status	CEO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 10,750,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 10,750,000 £268,750
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Vladimir Golovko
2	Reason for notification
a)	Position / status	COO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 8,600,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 8,600,000 £215,000
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Malcolm Groat
2	Reason for notification
a)	Position / status	Non-Executive Chairman
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 2,150,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 2,150,000 £53,750
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Andrey Katyshkov
2	Reason for notification
a)	Position / status	CFO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 4,300,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 4,300,000 £107,500
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCEANFFELANFFF

Close

×

Neville Registrars is delighted to welcome Zaim Credit Systems Plc as the newest addition to its list of client companies.

Zaim Credit Systems Plc is the holding company of a Russian based financial services company Zaim Express LLC

Further information can be found on the Company's website: http://www.zaimcreditsystemsplc.com

 

 

 

Close

×

RNS Number : 8050R

Pennant International Group PLC

31 October 2019

 

                                                                                                                                                           

FOR IMMEDIATE RELEASE                                                                    31 October 2019

 

PENNANT INTERNATIONAL GROUP PLC

 

New £3.4 Million Contract Award and Qatar Update

 

Pennant International Group plc ("Pennant", the "Group", or the "Company"), the AIM quoted supplier of integrated training and support solutions, products and services which train and assist operators and maintainers in the defence and regulated civilian sectors, is pleased to announce the following contracts update.

 

New Contract Award

 

Pennant has been awarded a major new contract by a UK OEM valued at circa £3.4 million for the design and build of a helicopter maintenance training aid which will comprise a full-size representation of the relevant airframe to enable UK military training on 'anti-surface' weapons systems.

 

The contract is an engineered-to-order programme, whereby revenue will be recognised on a 'percentage of cost completed' basis, as the programme runs across 2020 and 2021, with final acceptance due in Q4 2021.

 

Qatar Progress

 

As previously announced, the Group had budgeted to realise key revenue streams in the second half of 2019 upon acceptance of training aids for the Qatar programme.

 

Pennant is now pleased to report that all four IAMT devices for Qatar have achieved acceptance, enabling the revenues and profits associated with those training aids to be recognised in the current year.

 

Two further products are on schedule for acceptance testing in December 2019.

 

Phil Walker, Group CEO, commented: "After a challenging period, it is great to see the hard work of Pennant's staff pay off, with products being successfully completed on schedule and on budget for the Qatar programme, plus the conversion of one of a number of key opportunities in our substantial single-source pipeline into a valuable contract award."

 

 

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial & Risk Director	+44 (0) 1452 714 914
WH Ireland Limited (Nomad and Broker)	www.whirelandcb.com
Mike Coe Chris Savidge	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTEAEEFDLLNFFF

Close